Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Spero Therapeutics, Inc. (SPRO)
apnews.com
business
2022-05-31 23:32:33

SAN DIEGO--(BUSINESS WIRE)--May 31, 2022--The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Spero Therapeutics, Inc. (NASDAQ: SPRO) securities between October 28, 2021 and May 2, 2022. The complaint alleges violations of the Securities Exchange Act of 1934. Spero is clinical-stage biopharmaceutical company that focuses on developing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
